en
svXspray Pharma Chariman divests 4,000 shares to cover Danish capital gains tax on unrealised gains on Xspray Pharma shares
Xspray Pharma’s Chairman, Michael Wolff Jensen’s private, fully owned holding company MWJ Partners ApS has sold 4,000 shares in Xspray Pharma. The proceeds cover incurred Danish capital gains tax, which is charged on unrealized capital gains on MWJ Partners’ holding of shares in Xspray Pharma. After the transaction, Michael Wolff Jensen holds 31,864 shares and […]
Read moreNotice of annual general meeting in Xspray Pharma AB (publ)
The shareholders of Xspray Pharma AB (publ), reg. no. 556649-3671 are hereby summoned to attend the annual general meeting ("AGM") on Monday, 14 May, 2018, at 11.00 a.m. CET at IVA Konferenscenter’s premises on Grev Turegatan 16 in Stockholm, Sweden. Right to participate Those who have been recorded as shareholders in the share register kept […]
Read moreBulletin from the extraordinary general meeting of Xspray Pharma AB (publ)
On 20 February, 2018, Xspray Pharma AB (publ) held an extraordinary general meeting. The following resolution, among others, were passed at the general meeting. Directed issue of shares The general meeting resolved, in accordance with the board of directors’ proposal, to carry out a directed issue of not more than 1,350,000 new shares, entailing an […]
Read moreNotice of extraordinary general meeting in Xspray Pharma AB (publ)
The shareholders of Xspray Pharma AB (publ) are hereby summoned to attend the extraordinary general meeting (“EGM”) on Tuesday, 20 February, 2018, at 11.00 CET at Advokatfirman Vinge’s offices on Smålandsgatan 20 in Stockholm, Sweden. Right to participate Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as […]
Read moreXspray Pharma proposes a directed issue of 1,350,000 shares corresponding to approximately SEK 88 million to expand the product portfolio
The board of directors of Xspray Pharma AB (publ) has resolved to propose a directed share issue of 1,350,000 shares at a subscription price of SEK 65 per share, representing a discount of 2 percent compared to the volume weighted average price during the last five trading days. The share issue will provide Xspray Pharma […]
Read moreXspray Pharma enters Manufacturing Agreement with NerPharMa for its lead product candidate; HyNap-Dasa
Xspray Pharma AB, a specialty pharmaceutical company, today announced that it has signed a Manufacturing and Supply Agreement with NerPharMa S.r.l., a pharmaceutical manufacturing company in Milan, Italy, to manufacture its lead product candidate HyNap-Dasa. The agreement covers the clinical and world-wide commercial supply of HyNap-Dasa, and includes production of both drug substance and the […]
Read more